Aflibercept Injection [Eylea]

Preclinical

Aflibercept Injection [Eylea] is one of 24 therapeutic programs targeting Diabetic Macular Edema. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diabetic Macular EdemaActive, not recruiting

Diabetic Macular EdemaPreclinical

Active, not recruiting

Competition

Competitive Landscape

32 competitors in Diabetic Macular Edema

#DrugCompanyPhaseTrials

Eylea

Regeneron

Approved

54 2

Vabysmo

Roche

Approved

12 3

Beovu

Novartis

Approved

6 4

Decadron

AAspen Global Incorporated

Approved

13 5

Amaryl

Sanofi

Approved

1 6

Aldactone

Pfizer

Approved

1 7

Kenalog

BBassett Healthcare

Approved

4 8

Klor-Con

Jardiance

1 10

Intravitreal Ranibizumab

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalActive, not recruiting

Diabetic Macular Edema

NCT02645266

Clinical

Trials by Indication[1]

Diabetic Macular Edema1 trial

Mean Visual Acuity Changes Following Five Injections of Aflibercept and the Relationship Between Ocular and Serum Cytokine Levels and Mean Visual Acuity Gains in DME Patients

Active, not recruiting·MMcMaster University·Preclinical·NCT02645266·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Aflibercept Injection [Eylea]. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Aflibercept Injection [Eylea]. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — McMaster University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: MMcMaster University

Aflibercept Injection [Eylea]

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Diabetic Macular Edema1 trial

References

Drug Info

Quick Facts

Related News